We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this morning, May 10th, in Nature Medicine! Nature Medicine is one of the top scientific journals across fields, underscoring the significance of our findings. This is, without question, a monumental accomplishment.
We want to personally acknowledge the effort it took to reach this milestone. It would not have been possible without the contributions of each and every one of you, our clinical researchers and therapists, our participants, and everyone who has supported our work over the years. Your skill, dedication, and commitment made our vision a reality. We also recognize the immense amount of work and determination it took to get to where we are.
A big thank you to the Phase 3 team, and cross-functional teams at MAPS PBC who made this study a success, and to all the dedicated teams across departments at MAPS. This work would not be possible without all of your efforts; from designing and implementing the MAPP1 protocol, to training therapists, and supporting clinical research teams, from gathering funding for our research, to advocating for policy change, and educating people about the work we do. We wouldn’t be here without the efforts of each and every one of you!
The New York Time’s ran the following article on the front page of today’s issue. We couldn’t agree with the title more: The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
Special thanks to the MAPS Communications and Marketing team for your heroic efforts spreading the news of the MAPP1 results far and wide!
– Amy Emerson, Chief Executive Officer (CEO) of MAPS Public Benefit Corporation (MAPS PBC)